Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Current Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023

Cyteir Therapeutics Inc Current Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The current ratio assesses a company's short-term liquidity and its ability to cover its current liabilities with its current assets. It is calculated by dividing current assets by current liabilities. This ratio indicates the number of times a company's current assets can cover its current liabilities. A higher current ratio suggests better liquidity and a stronger ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Cyteir Therapeutics Inc Current Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 23.12, a 18.69% change year over year.
  • Cyteir Therapeutics Inc Current Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 19.48.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email